Journal article
Erythrocyte membrane fatty acid concentrations and myelin integrity in young people at ultra-high risk of psychosis
M Collins, C Bartholomeusz, C Mei, M Kerr, J Spark, N Wallis, A Polari, S Baird, K Buccilli, SJA Dempsey, N Ferguson, M Formica, M Krcmar, AL Quinn, C Wannan, S Oldham, A Fornito, Y Mebrahtu, A Ruslins, R Street Show all
Psychiatry Research | ELSEVIER IRELAND LTD | Published : 2024
Abstract
Decreased white matter (WM) integrity and disturbance in fatty acid composition have been reported in individuals at ultra-high risk of psychosis (UHR). The current study is the first to investigate both WM integrity and erythrocyte membrane polyunsaturated fatty acid (PUFA) levels as potential risk biomarkers for persistent UHR status, and global functioning in UHR individuals. Forty UHR individuals were analysed at baseline for erythrocyte membrane PUFA concentrates. Tract-based spatial statistics (TBSS) was used to analyse fractional anisotropy (FA) and diffusivity measures. Measures of global functioning and psychiatric symptoms were evaluated at baseline and at 12-months. Fatty acids an..
View full abstractRelated Projects (4)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
Research reported in this publication was supported National Health and Medical Research Council Australia (Grant No. 1067040 [to GPA] ) , Senior Research Fellowship Grants No. 1080963 [to GPA] and No. 1137687 [to BN] , and Senior Principal Research Fellowship Grant No. 1155508 [to PDM] .GPA has received grant funding from the National Health and Medical Research Council of Australia, the Stanley Foundation, NIH, and Wellcome Trust. BN has received grant funding from the National Health and Medical Research Council of Australia, the Stanley Foundation, NIH, and Wellcome Trust. PDM has received past unrestricted grant funding from Janssen-Cilag, AstraZeneca, Eli Lilly, Novartis, and Pfizer, and honoraria for consultancy and teaching from Janssen-Cilag, Eli Lilly, Pfizer, AstraZeneca, Roche, Bristol Meyers Squibb, and Lundbeck. He has received grant funding from the Colonial Foundation, the National Health and Medical Research Council of Australia, Australian Research Council, NARSAD, the Stanley Foundation, NIH, Wellcome Trust, and the Australian and Victorian governments. The other authors report no biomedical financial interests or potential conflicts of interest.r CA 2773031 issued. GPA has received grant funding from the National Health and Medical Research Council of Australia, the Stanley Foundation, NIH, and Wellcome Trust. BN has received grant funding from the National Health and Medical Research Council of Australia, the Stanley Foundation, NIH, and Wellcome Trust. PDM has received past unrestricted grant funding from Janssen-Cilag, AstraZeneca, Eli Lilly, Novartis, and Pfizer, and honoraria for consultancy and teaching from Janssen-Cilag, Eli Lilly, Pfizer, AstraZeneca, Roche, Bristol Meyers Squibb, and Lundbeck. He has received grant funding from the Colonial Foundation, the National Health and Medical Research Council of Australia, Australian Research Council, NARSAD, the Stanley Foundation, NIH, Wellcome Trust, and the Australian and Victorian governments. The other authors report no biomedical financial interests or potential conflicts of interest. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; prep-aration, review, or approval of the manuscript; and decision to submit the manuscript for publication.